Highlights and Quick Summary
- Net Debt/EBITDA for the quarter ending June 30, 2022 was 0.01 (a -100.3% decrease compared to previous quarter)
- Year-over-year quarterly Net Debt/EBITDA decreased by -99.17%
- Annual Net Debt/EBITDA for 2021 was 0.11 (a 1.6% increase from previous year)
- Annual Net Debt/EBITDA for 2021 was 0.11 (a -103.77% decrease from previous year)
- Annual Net Debt/EBITDA for 2020 was -2.98 (a -88.72% decrease from previous year)
Visit stockrow.com/BFAGY
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Debt/EBITDA of Biofrontera AG Sponsored ADR
Most recent Net Debt/EBITDAof BFAGY including historical data for past 10 years.Interactive Chart of Net Debt/EBITDA of Biofrontera AG Sponsored ADR
Biofrontera AG Sponsored ADR Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | – | 0.01 | -3.5 | – |
| 2021 | 0.15 | 1.26 | 0.0 | 3.44 | 0.11 |
| 2020 | 0.0 | -3.56 | 0.0 | -2.22 | -2.98 |
| 2019 | – | 0.0 | 0.0 | 0.44 | -0.55 |
| 2018 | – | – | – | 2.08 | 0.37 |
| 2017 | – | – | 0.28 | 2.58 | -0.07 |
| 2016 | -3.98 | – | – | – | 1.15 |
Business Profile of Biofrontera AG Sponsored ADR
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic